Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming-Reference-Cited by-同舟云学术

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Published:2017-04 Issue:7649 Volume:544 Page:250-254
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Tian Lin,Goldstein Amit,Wang Hai,Ching Lo Hin,Sun Kim Ik,Welte Thomas,Sheng Kuanwei,Dobrolecki Lacey E.,Zhang Xiaomei,Putluri Nagireddy,Phung Thuy L.,Mani Sendurai A.,Stossi Fabio,Sreekumar Arun,Mancini Michael A.,Decker William K.,Zong Chenghang,Lewis Michael T.,Zhang Xiang H.-F.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature21724.pdf

Reference36 articles.

1. Ebos, J. M. L. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009)

2. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009)

3. Goel, S., Wong, A. H.-K. & Jain, R. K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med. 2, a006486 (2012)

4. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008)

5. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012)

Cited by 586 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural products‐based antiangiogenic agents: New frontiers in cancer therapy;Food Frontiers;2024-09

2. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

3. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

4. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances;Signal Transduction and Targeted Therapy;2024-08-28

5. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy;BMC Cancer;2024-08-20